What is HC Wainwright’s Estimate for Surrozen Q3 Earnings?

Surrozen, Inc. (NASDAQ:SRZN) – HC Wainwright reduced their Q3 2026 earnings estimates for Surrozen in a research note issued on Monday, August 10th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.33) per share for the quarter, down from their previous forecast of ($1.19). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($7.20) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2026 earnings at ($1.31) EPS, FY2027 earnings at ($5.01) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($5.47) EPS and FY2030 earnings at ($5.53) EPS.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.88. The business had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.47 million.

Several other equities analysts also recently issued reports on the stock. TD Cowen assumed coverage on shares of Surrozen in a research note on Tuesday, April 21st. They set a “buy” rating for the company. Zacks Research upgraded Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Surrozen has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Surrozen Stock Performance

NASDAQ SRZN opened at $25.05 on Wednesday. The firm’s fifty day moving average price is $22.91 and its two-hundred day moving average price is $25.50. The stock has a market cap of $290.83 million, a PE ratio of -0.62 and a beta of 0.52. Surrozen has a fifty-two week low of $9.66 and a fifty-two week high of $35.00.

Insider Buying and Selling

In other news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the firm’s stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the completion of the sale, the insider directly owned 574,047 shares in the company, valued at $12,198,498.75. This trade represents a 36.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 31.74% of the company’s stock.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC lifted its position in shares of Surrozen by 557.1% during the 4th quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after buying an additional 611,497 shares in the last quarter. Braidwell LP grew its holdings in shares of Surrozen by 235.7% in the fourth quarter. Braidwell LP now owns 470,000 shares of the company’s stock valued at $10,622,000 after acquiring an additional 330,000 shares in the last quarter. Spruce Street Capital LP bought a new position in shares of Surrozen in the fourth quarter valued at approximately $9,764,000. 5AM Venture Management LLC increased its position in shares of Surrozen by 25.0% during the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock valued at $8,758,000 after acquiring an additional 77,500 shares during the last quarter. Finally, Kalehua Capital Management LLC purchased a new stake in shares of Surrozen during the fourth quarter valued at approximately $8,705,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.